Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Rectal Neoplasms 1Precancerous Conditions 1Hearing Loss 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Radiotherapy 26Cisplatin 17Fluorouracil 13Paclitaxel 10Carboplatin 6Chemotherapy, Adjuvant 5Cetuximab 5Immunohistochemistry 4Docetaxel 4Radiotherapy, Intensity-Modulated 3Immunoenzyme Techniques 3Hydroxyurea 3Gemcitabine 3Gefitinib 3Filgrastim 3Bortezomib 3sargramostim 2bintrafusp alfa protein, human 2aldesleukin 2Tetrahydrouridine 2SS1(dsFv)PE38 2Radiotherapy, Conformal 2Polymerase Chain Reaction 2Oxaliplatin 2Neoadjuvant Therapy 2Methotrexate 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gene Expression Profiling 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Head and Neck Neoplasms × Atorvastatin × Clear all
NCT04915183 2026-06-05

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡